Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.14
$0.01(0.89%)
At close: 4:00 PM EDT
$1.14
$0.01(0.89%)
Day’s Range― - ―
52-Week Range$1.03 - $24.30
Previous CloseN/A
Volume3.02K
Average Volume (3M)1.09M
Market Cap
$4.50M
Enterprise Value-$10.19
Total Cash (Recent Filing)$13.75M
Total Debt (Recent Filing)$678.34K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.15
Shares Outstanding3,877,337
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.3
Revenue Forecast (FY)$35.40M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage limits interest-burden pressure and reduces refinancing risk. This gives Sunshine Biopharma greater financial flexibility than a highly indebted peer while it works to improve earnings and cash generation.
Underlying Product MarginA positive gross margin shows that commercialized products generate economic value before operating expenses. If revenue stabilizes and costs are controlled, this gross-profit base could support a path toward improved operating performance.
Diversified Pharmaceutical PortfolioExposure to both generic pharmaceuticals and proprietary or oncology-focused medicines provides multiple avenues for commercial growth. This portfolio structure can reduce reliance on a single product or therapeutic opportunity over time.
Bears Say
Persistent Revenue And Profitability WeaknessThe sharp revenue decline and continuing net losses indicate that commercialization momentum and operating scale remain unproven. Sustained weakness could limit investment capacity and make the company’s growth strategy harder to execute.
Ongoing Cash BurnNegative operating and free cash flow means the business is not currently self-funding its operations. Continued cash consumption may require external financing or balance-sheet resources, increasing dependence on capital markets.
Equity Dilution RiskReliance on equity issuance to support operations can dilute existing shareholders and complicate future capital structure management. Warrant repricing may further increase potential dilution as financing needs persist.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $1.03 and its highest was $24.30 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $4.50M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Nov 10, 2026 which is in 76 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on Aug 05, 2026. The company reported -$1.146 earnings per share for the quarter, beating the consensus estimate of -$1.15 by $0.004.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 3,877,337 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$1.146 in its last earnings report, beating expectations of -$1.15. Following the earnings report the stock price went up 1.527%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
1.76% Insiders
<0.01% Other Institutional Investors
98.24% Public Companies and
Individual Investors